Multiple Sclerosis, Relapsing-Remitting Clinical Trials

24 recruiting

Frequently Asked Questions

Common questions about Multiple Sclerosis, Relapsing-Remitting clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 24 trials

Recruiting
Phase 1Phase 2

Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy

Multiple Sclerosis (MS)Multiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Primary Progressive+4 more
University of California, San Francisco74 enrolled1 locationNCT05359653
Recruiting
Not Applicable

Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS

Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Secondary Progressive
Shirley Ryan AbilityLab22 enrolled1 locationNCT06390930
Recruiting
Phase 3

Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting
Celgene194 enrolled33 locationsNCT06408259
Recruiting
Not Applicable

Fatigue Alleviation Through Neuromodulating Therapy in Multiple Sclerosis

FatigueMultiple Sclerosis, Relapsing-Remitting
Danish Research Centre for Magnetic Resonance60 enrolled1 locationNCT06569550
Recruiting

Clinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis (Switzerland)

Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Secondary Progressive+1 more
University Hospital, Basel, Switzerland100 enrolled1 locationNCT06526364
Recruiting
Not Applicable

Motor Learning of Fall Resistant Skills Through Slip and Trip Exposure in Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting
Georgia State University64 enrolled1 locationNCT06919900
Recruiting
Not Applicable

Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis

Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Chronic Progressive
Cionic, Inc.14 enrolled1 locationNCT05964829
Recruiting
Not Applicable

Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimulation

Multiple Sclerosis, Relapsing-Remitting
The University of Texas at Dallas100 enrolled1 locationNCT05958381
Recruiting
Not Applicable

Intermittent Hypoxia in Persons With Multiple Sclerosis

Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Secondary Progressive
Shirley Ryan AbilityLab21 enrolled1 locationNCT06276634
Recruiting
Phase 2

TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting
University Hospital, Strasbourg, France40 enrolled5 locationsNCT03910738
Recruiting
Not Applicable

Retinal Neuro-vascular Coupling in Patients With Multiple Sclerosis

Optic NeuritisMultiple Sclerosis, Relapsing-Remitting
Medical University of Vienna50 enrolled1 locationNCT03401879
Recruiting
Phase 4

Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting
University of California, San Francisco5 enrolled1 locationNCT06495593
Recruiting
Not Applicable

Multiple Sclerosis and the Effects of Ketogenic Diet Therapy

Multiple Sclerosis, Relapsing-Remitting
IRCCS National Neurological Institute "C. Mondino" Foundation111 enrolled1 locationNCT06715436
Recruiting
Not Applicable

Light Stimulation to Improve Visual Function After Optic Neuritis in Persons with Multiple Sclerosis

Optic NeuritisMultiple Sclerosis, Relapsing-Remitting
Technical University of Munich50 enrolled1 locationNCT06389968
Recruiting

Multiple Sclerosis Treatment With Autologous Hematopoietic Stem Cell Transplantation in the Netherlands

Multiple Sclerosis, Relapsing-Remitting
Amsterdam UMC, location VUmc24 enrolled2 locationsNCT06567197
Recruiting

Development of Camera Based Gait Quality Measure for Persons With Multiple Sclerosis

Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Secondary Progressive+1 more
Shirley Ryan AbilityLab40 enrolled1 locationNCT06516458
Recruiting
Not Applicable

Effects of a Combined Supplementation of Conjugated Linoleic Acid (CLA) and Probiotics (Vivomixx®) as add-on to a First-line Immunotherapy in Relapsing-remitting Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting
Universität Münster100 enrolled4 locationsNCT05920018
Recruiting
Phase 2

RC18 in Patients With Relapsing Remitting Multiple Sclerosis:a Phase II Trial

Multiple Sclerosis, Relapsing-Remitting
RemeGen Co., Ltd.30 enrolled1 locationNCT04625153
Recruiting

MS-ResearchBiomarkerS

Neurologic DisorderMultiple SclerosisClinically Isolated Syndrome+8 more
Cedars-Sinai Medical Center1,000 enrolled1 locationNCT05204459
Recruiting

Biomarkers of aHSCT

Multiple Sclerosis, Relapsing-Remitting
Sheffield Teaching Hospitals NHS Foundation Trust15 enrolled1 locationNCT06195800